Close Menu

NEW YORK – PerkinElmer said on Monday that it expects revenue growth of about 66 percent for the fourth quarter of 2020.

PerkinElmer posted total revenues of $805.5 million in Q4 2019.

Organically, revenue growth is anticipated to be around 63 percent for the three months ended Jan. 3, it said, while GAAP earnings per share from continuing operations are expected to be at least $2.88 and adjusted EPS from continuing operations are expected to be at least $3.60, well above the Wall Street consensus forecast of $2.79.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.